Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

New Jersey and you

  • News

Executive Summary

Former New Jersey Rep. Franks (R) named president of the pharmaceutical interest group HealthCare Institute of New Jersey, effective Aug. 1. During his four terms in the House, Franks co-sponsored legislation to extend the patent life for Schering-Plough's Claritin. Schering, Pfizer, Merck and Novartis contributed to Franks' campaigns, including his unsuccessful bid for Senate in 2000. Franks succeeds William Tremayne, who is retiring. The HealthCare Institute is chaired by Merck CEO Ray Gilmartin

Table

View full table

Tags:
Latest Headlines

Cancer Trials: FDA Wants Lower Performance Status Eligibility But Primary Analysis Exclusion OK

US FDA's Califf Defends Agency Work On Marijuana Rescheduling, Animal Testing

Overall Survival Is Not A Required Primary Endpoint In All Cancer Trials, US FDA Says

Australia Calls For Companion Testing Plans For Drugs Requiring A CDx

See All
UsernamePublicRestriction

Register

PS038151

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By